system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: Aconitine, Adult, Animals, Ascitic Fluid, Bridged Bicyclo Compounds, Heterocyclic, Disease Models, Animal, Endometriosis, Endometrium, Female, Gene Expression Regulation, Humans, Interleukin-1beta, Lipopolysaccharides, Macrophage Activation, Macrophages, Peritoneal, Mice, Nicotine, Primary Cell Culture, Quinuclidines, RNA, Messenger, Severity of Illness Index, Signal Transduction, alpha7 Nicotinic Acetylcholine Receptor.
user
Does alpha-7 nicotinic acetylcholine receptor ( nAChR ) agonist inhibit the development of endometriosis by regulating inflammation? Context: We investigated α-7 nAchR expression in human peritoneal macrophages and examined whether activation of nAchR might be a new therapy for endometriosis. Human peritoneal fluid mononuclear cells (PFMC) were stimulated with lipopolysaccharide (LPS) in the presence of α-7 nAChR agonists. In a murine endometriosis model, α-7 nAChR modulators were administered. Human PFMC expressed α-7 nAChR at the mRNA and protein levels. Activation of α-7 nAChR with its agonists led to significant (P<.01) suppression of LPS-induced interleukin (IL) -1β expression. In a murine endometriosis model, one week after inoculation of endometrium to the peritoneal cavity, α-7 nAChR agonist significantly suppressed the expression of IL-1β mRNA (P<.01), which was negated when α-7 nAChR antagonist was administered simultaneously. α-7 nAChR agonist significantly suppressed the formation of endometriotic lesions, which was reversed with α-7 nAChR antagonist.
assistant
Activation of nAChR might be a new candidate for treatment of endometriosis. Final Decision: yes